ERBB2 and breast carcinoma: Specifically, ganetespib showed stronger anti-tumor activity compared to tanespimycin over a broader range of breast cancer subtypes, including HER2-normal cancer and triple-negative breast cancer (TNBC), with a more favorable safety profile, including lack of hepatotoxicity and ocular toxicity [18, 19].